Table 5. Clinical parameters and survival of non-adenocarcinoma patients harboring EGFR mutations.
| Histology | Mutation status | Age (yr)/Sex (M, W) | Clinical Stage | Cyfra21–1 (ng/ml) | CEA (ng/ml) | SCCA (ng/ml) | NSE (ng/ml) | DFS (mo) | OS (mo) |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | Exon 19 deletion | 55/W | I | 1.69 | 30.74 | 0.3 | 7.25 | 24 | 43.7 |
| Squamous cell carcinoma | Exon 19 deletion | 55/M | II | 39.38 | 2.32 | 0.6 | 33.36 | 9.1 | 16.2 |
| Squamous cell carcinoma | Exon 19 deletion | 55/W | I | 3.2 | 4.29 | 0.6 | 19.64 | 65 | 65 |
| Squamous cell carcinoma | Exon 19 deletion | 55/W | IIIA | 14.55 | 16.94 | 0.7 | 29.81 | 36.1 | 37.6 |
| Squamous cell carcinoma | Exon 19 deletion | 52/W | IIIA | 21.27 | 17.08 | 18.6 | 12.81 | 23.9 | 32.7 |
| Squamous cell carcinoma | Exon 19 deletion | 68/M | I | 8.04 | 4.52 | 0.8 | 17.08 | 15 | 18.3 |
| Squamous cell carcinoma | Exon 19 deletion | 69/W | I | 3.86 | 4.05 | 0.4 | 10.3 | 14 | 24.4 |
| Squamous cell carcinoma | Exon 19 deletion | 71/M | IIIA | 6.28 | 2.12 | 1.6 | 8.38 | 13.2 | 33.5 |
| Squamous cell carcinoma | Exon 19 deletion | 67/W | IIIA | 14.74 | 2.08 | 5.5 | 13.47 | 12 | 13.2 |
| Squamous cell carcinoma | Exon 19 deletion | 52/W | I | 0.4 | 232.89 | 0.8 | 15.33 | 22 | 30.1 |
| Squamous cell carcinoma | Exon 19 deletion | 57/M | IIIA | 3.12 | 2.66 | 0.6 | 14.24 | 12 | 17.3 |
| Squamous cell carcinoma | L858R substitution | 48/W | IIIA | 7.7 | 13.44 | 0.6 | 33.95 | 5 | 7.1 |
| Squamous cell carcinoma | L858R substitution | 55/W | I | 9.91 | 255.4 | 0.3 | 33.49 | 2 | 16.2 |
| Squamous cell carcinoma | L858R substitution | 56/W | I | 2.64 | 31.4 | 0.8 | 12.3 | 28.3 | 28.3 |
| Squamous cell carcinoma | L858R substitution | 69/M | II | 2.38 | 2.39 | 1.3 | 10.67 | 21.2 | 21.2 |
| Adenosquamous carcinoma | Exon 19 deletion | 54/W | IIIA | 15.68 | 10.83 | 0.3 | 29.91 | 45.2 | 50.7 |
| Adenosquamous carcinoma | Exon 19 deletion | 45/W | IIIA | 3.89 | 69.86 | 0.6 | 14.52 | 54.7 | 54.7 |
| Adenosquamous carcinoma | Exon 19 deletion | 51/W | IIIA | 2.14 | 4.35 | 0.4 | 15.35 | 12 | 32.5 |
| Adenosquamous carcinoma | Exon 19 deletion | 58/W | II | 2.47 | 5.23 | 0.7 | 17.94 | 21.3 | 39.6 |
| Adenosquamous carcinoma | Exon 19 deletion | 48/W | IIIA | 1.84 | 16.04 | 0.5 | 12.76 | 37.5 | 43.7 |
| Adenosquamous carcinoma | Exon 19 deletion | 64/M | II | 3.91 | 6.24 | 0.5 | 21.18 | 12 | 23.4 |
| Adenosquamous carcinoma | L858R substitution | 61/M | II | 14.95 | 14.87 | 1 | 14.97 | 35 | 38.6 |
| Adenosquamous carcinoma | L858R substitution | 63/W | IIIA | 5.95 | 26.41 | 0.1 | 15.74 | 25 | 23.4 |
| Large cell lung carcinoma | Exon 19 deletion | 34/W | IIIA | 1.41 | 6.17 | 0.4 | 18.16 | 3 | 12.2 |
| Large cell lung carcinoma | L858R substitution | 65/W | II | 4.08 | 1.72 | 0.8 | 12.49 | 5 | 20.3 |
| Large cell lung carcinoma | L858R substitution | 71/W | I | 10.26 | 42.38 | 0.8 | 25.28 | 3 | 3 |
| Large cell lung carcinoma | L858R substitution | 72/M | I | 3.6 | 2.22 | 1.2 | 17.89 | 3 | 9.1 |